Shandong Suncadia Medicine
CompanyChina
Shandong Suncadia Medicine develops 3 assets, the furthest in phase 3 (HRS-7535 in type 2 diabetes). Mostly small molecule acting on Insulin/IGF-1 signalling and GLP1R; based in China.
- 3
- Assets
- Furthest stage
- Phase 3
- 13
- Trials
- 0
- Signals
Pipeline
3Oral GLP-1 receptor agonist
Phase 3, Small molecule, Insulin/IGF-1 signalling, GLP1R, type 2 diabetes
Phase 2, Small molecule, primary aldosteronism
Phase 1, Small molecule, diabetes, type 2 diabetes
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials14
- Signals1
- Similar companies6